Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of FCN-159 in adults with extracranial arteriovenous malformation
ChiCTR2400082235Phase 2Completed
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in extracranial arteriovenous malformation (EAVM), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective response rate by digital subtraction angiography at cycle 12. Started Mar 2024; status: completed.
02
Drugs
luvometinib
03
Conditions
extracranial arteriovenous malformation (EAVM)
Beyond the preview
Go deeper on ChiCTR2400082235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082235.